Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | RO7227166 |
Trade Name | |
Synonyms | RO 7227166|RO-7227166 |
Drug Descriptions |
RO7227166 binds to both CD19 and TNFRSF9 (4-1BB), potentially resulting in activation of anti-tumor immune response against tumor cells expressing CD19 (NCI Drug Dictionary). |
DrugClasses | CD19 Antibody 13 TNFRSF9 Antibody 15 |
CAS Registry Number | NA |
NCIT ID | C169052 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Obinutuzumab + RO7082859 + RO7227166 + Tocilizumab | Obinutuzumab RO7082859 RO7227166 Tocilizumab | 0 | 1 |
Obinutuzumab + RO7227166 + Tocilizumab | Obinutuzumab RO7227166 Tocilizumab | 0 | 1 |
RO7227166 | RO7227166 | 0 | 0 |